Cargando…

Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis

AIM: To evaluate circulating IL9 in inflammatory bowel disease and disease-associated anemia/cachexia and assess its potential as a mucosal healing marker. METHODS: Serum IL9 as well as other cytokines (IL1β, IL6, IL13, IFNγ, TNFα, and VEGF-A) were determined in 293 individuals: 97 patients with Cro...

Descripción completa

Detalles Bibliográficos
Autores principales: Matusiewicz, Malgorzata, Neubauer, Katarzyna, Bednarz-Misa, Iwona, Gorska, Sabina, Krzystek-Korpacka, Malgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473122/
https://www.ncbi.nlm.nih.gov/pubmed/28652656
http://dx.doi.org/10.3748/wjg.v23.i22.4039
_version_ 1783244247626940416
author Matusiewicz, Malgorzata
Neubauer, Katarzyna
Bednarz-Misa, Iwona
Gorska, Sabina
Krzystek-Korpacka, Malgorzata
author_facet Matusiewicz, Malgorzata
Neubauer, Katarzyna
Bednarz-Misa, Iwona
Gorska, Sabina
Krzystek-Korpacka, Malgorzata
author_sort Matusiewicz, Malgorzata
collection PubMed
description AIM: To evaluate circulating IL9 in inflammatory bowel disease and disease-associated anemia/cachexia and assess its potential as a mucosal healing marker. METHODS: Serum IL9 as well as other cytokines (IL1β, IL6, IL13, IFNγ, TNFα, and VEGF-A) were determined in 293 individuals: 97 patients with Crohn’s disease (CD) and 74 with ulcerative colitis (UC) and in 122 apparently healthy controls. The clinical activity of CD and UC was expressed in terms of the Crohn’s Disease Activity Index (CDAI) and the Mayo Scoring System (MDAI), respectively, and the severity of bowel inflammation in UC patients was assessed using Mayo endoscopic score. Cytokine concentrations were measured by a flow cytometry-based method using Luminex xMAP(®) technology. High-sensitive C-reactive protein concentrations (hsCRP) were determined in CD and UC patients using the enhanced immunoturbidimetric method. RESULTS: Systemic IL9 was significantly lower in healthy individuals [9 pg/mL (95%CI: 8.2-10)] than in patients with inflammatory bowel disease (IBD): both inactive [14.3 pg/mL (11.9-19.9)] and active [27.6 pg/mL (24.5-32), P < 0.0001]. Cytokine concentrations were significantly higher in active CD [27.4 pg/mL (23.4-32.2)] and in active UC [32.7 pg/mL (27-38.9)] compared to inactive diseases [15.9 pg/mL (10.8-23.4) in CD and 19.4 pg/mL (13.9-27.1) in UC, P = 0.001]. IL9 correlated weakly with CDAI (ρ = 0.32, P = 0.003) and MDAI (ρ = 0.35, P = 0.002) and strongly with endoscopic inflammation in UC (ρ = 0.74, P < 0.0001). As a negative marker of mucosal healing (MH), IL9 had an accuracy superior to hsCRP and IL6 [97% (P < 0.0001), 67% (P = 0.071), and 55% (P = 0.525), respectively]. IL9 was significantly higher in cachectic IBD patients [30.25 pg/mL (24.4-37.5) vs 21.88 pg/mL (18-26.5), P = 0.026] and negatively correlated with hemoglobin concentrations (ρ = -0.27, P < 0.001). Multiple regression showed IL1β and IL13 to be the independent predictors of circulating IL9 in healthy individuals, IFNγ or IL6 in active and inactive UC, respectively, and IL13 and VEGF-A in both active and inactive CD. CONCLUSION: The systemic IL9 level is higher in IBD and corresponds with endoscopic inflammation, suggesting its possible application as a negative marker of mucosal healing in UC.
format Online
Article
Text
id pubmed-5473122
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-54731222017-06-26 Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis Matusiewicz, Malgorzata Neubauer, Katarzyna Bednarz-Misa, Iwona Gorska, Sabina Krzystek-Korpacka, Malgorzata World J Gastroenterol Case Control Study AIM: To evaluate circulating IL9 in inflammatory bowel disease and disease-associated anemia/cachexia and assess its potential as a mucosal healing marker. METHODS: Serum IL9 as well as other cytokines (IL1β, IL6, IL13, IFNγ, TNFα, and VEGF-A) were determined in 293 individuals: 97 patients with Crohn’s disease (CD) and 74 with ulcerative colitis (UC) and in 122 apparently healthy controls. The clinical activity of CD and UC was expressed in terms of the Crohn’s Disease Activity Index (CDAI) and the Mayo Scoring System (MDAI), respectively, and the severity of bowel inflammation in UC patients was assessed using Mayo endoscopic score. Cytokine concentrations were measured by a flow cytometry-based method using Luminex xMAP(®) technology. High-sensitive C-reactive protein concentrations (hsCRP) were determined in CD and UC patients using the enhanced immunoturbidimetric method. RESULTS: Systemic IL9 was significantly lower in healthy individuals [9 pg/mL (95%CI: 8.2-10)] than in patients with inflammatory bowel disease (IBD): both inactive [14.3 pg/mL (11.9-19.9)] and active [27.6 pg/mL (24.5-32), P < 0.0001]. Cytokine concentrations were significantly higher in active CD [27.4 pg/mL (23.4-32.2)] and in active UC [32.7 pg/mL (27-38.9)] compared to inactive diseases [15.9 pg/mL (10.8-23.4) in CD and 19.4 pg/mL (13.9-27.1) in UC, P = 0.001]. IL9 correlated weakly with CDAI (ρ = 0.32, P = 0.003) and MDAI (ρ = 0.35, P = 0.002) and strongly with endoscopic inflammation in UC (ρ = 0.74, P < 0.0001). As a negative marker of mucosal healing (MH), IL9 had an accuracy superior to hsCRP and IL6 [97% (P < 0.0001), 67% (P = 0.071), and 55% (P = 0.525), respectively]. IL9 was significantly higher in cachectic IBD patients [30.25 pg/mL (24.4-37.5) vs 21.88 pg/mL (18-26.5), P = 0.026] and negatively correlated with hemoglobin concentrations (ρ = -0.27, P < 0.001). Multiple regression showed IL1β and IL13 to be the independent predictors of circulating IL9 in healthy individuals, IFNγ or IL6 in active and inactive UC, respectively, and IL13 and VEGF-A in both active and inactive CD. CONCLUSION: The systemic IL9 level is higher in IBD and corresponds with endoscopic inflammation, suggesting its possible application as a negative marker of mucosal healing in UC. Baishideng Publishing Group Inc 2017-06-14 2017-06-14 /pmc/articles/PMC5473122/ /pubmed/28652656 http://dx.doi.org/10.3748/wjg.v23.i22.4039 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Case Control Study
Matusiewicz, Malgorzata
Neubauer, Katarzyna
Bednarz-Misa, Iwona
Gorska, Sabina
Krzystek-Korpacka, Malgorzata
Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis
title Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis
title_full Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis
title_fullStr Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis
title_full_unstemmed Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis
title_short Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis
title_sort systemic interleukin-9 in inflammatory bowel disease: association with mucosal healing in ulcerative colitis
topic Case Control Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473122/
https://www.ncbi.nlm.nih.gov/pubmed/28652656
http://dx.doi.org/10.3748/wjg.v23.i22.4039
work_keys_str_mv AT matusiewiczmalgorzata systemicinterleukin9ininflammatoryboweldiseaseassociationwithmucosalhealinginulcerativecolitis
AT neubauerkatarzyna systemicinterleukin9ininflammatoryboweldiseaseassociationwithmucosalhealinginulcerativecolitis
AT bednarzmisaiwona systemicinterleukin9ininflammatoryboweldiseaseassociationwithmucosalhealinginulcerativecolitis
AT gorskasabina systemicinterleukin9ininflammatoryboweldiseaseassociationwithmucosalhealinginulcerativecolitis
AT krzystekkorpackamalgorzata systemicinterleukin9ininflammatoryboweldiseaseassociationwithmucosalhealinginulcerativecolitis